Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8

"Great news. Income from sales up 74% from the top income reported in 2021 / 2022

This is a really good income level showing the effectiveness of Viraleze for Covid and other respiratory diseases is being heard in the world community"

Honestly you statement in reply to quarterly are so far off the mark from reality it is impossible to understand your reasoning.

Please put up some sort of reasoning in regards to Sales where you imply that any number in this report in regards to " sales" in great???? I await your detailed commentary.
It is a listed company with massive overheads selling pennies worth of product and losing money hand over fist !!!


It is doing some contract lab research of which if successful it may have a interest in it but at rate they are going for any further stage it will be unable to fund its share of costs so will simply be diluted.
Meanwhile no hard numbers or markets and lots of wish washy childhood statements ( calling them motherhood would actually means they were mature serious statements IMO ) that shareholders had hoped would disappear with management change - apparently not
Shareholders deserve much better
Go through it line by line and take out all the spin and cliche and look at what is left - wow - information is real thin on what is going on IMO

Your comment on Viraleze " really good income level showing the effectiveness of Viraleze for Covid" is simply preposterous and shown by the level or industry and consumer interest which appears to be stuff all in the big picture

With such small income the fact they haven't announced dollar value or volume of new deal pretty much tells you it didn't meet reporting level to be a major contributor. So it either is a high rebate scheme to launch where SPL pays all costs or heavily discounted or very small order to start with IMO.